Stockreport

Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances [Yahoo! Finance]

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF The broker maintains its 'outperform' rating and $16 price target on shares trading at $4.97 Wedbush Securities has reiterated its bullish stance on Rocket Pharmaceut [Read more]